# US 2022/0276239 A1 · Method for accurate diagnosis of a disease targeting biomarkers in liquid biopsy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0276239 A1
- Document ID: US20220276239A1
- Status: Published application
- Kind: A1
- Application number: 17/663,670
- Filed: 2022-05-17
- Published: 2022-09-01
- Earliest claimed: 2017-03-28
- Assignees: Phase Scientific International, Ltd.
- Applicants: Phase Scientific International, Ltd.
- Inventors: Yin To CHIU
- Web page: https://patentgrep.com/patent/US20220276239A1

## CPC

- G01N 33/54386: {Analytical elements}
- G01N 33/575: for cancer
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to a method for improving the detection and diagnosis targeting biomarkers using an aqueous two-phase system (ATPS). In one embodiment, the present invention provides a method for improving a diagnostic procedure involving the detection or quantification of one or more biomarkers in liquid biopsy, the method comprises contacting a porous material embedded with ATPS components with a liquid biopsy containing the biomarkers, purifying and concentrating the target biomarkers, and providing a product comprising the target biomarkers for performing the diagnostic procedure.

## Claims

### Claim 1

A method for accurate diagnosis of a disease, comprising the steps of:
(a) providing a sample solution comprising a target biomarker of said disease;
(b) providing a porous material embedded with components of an aqueous two-phase system (ATPS), wherein said components form two phase solutions when an aqueous solution travels through said porous material so that one phase solution travels faster than the other phase solution;
(c) allowing said porous material to wick said sample solution, wherein the target biomarker in the sample solution partitions into the faster moving phase solution and becomes concentrated at the front of the faster moving phase solution;
(d) applying a washing buffer on the ATPS to wash off impurities from said porous material, wherein the target biomarker is retained in the porous material;
(e) drying and storing said porous material containing the target biomarker;
(f) eluting the target biomarker from the front of the faster moving phase solution by an elution buffer, resulting in a final solution containing the target biomarker; and
(g) subjecting said final solution to a diagnostic assay for detection and quantification of said target biomarker;
wherein the target biomarker is selected from the group consisting of alpha-fetoprotein (AFP), Cancer Antigen (CA15-3), and cell-free DNA, and
wherein said ATPS components are selected from polymers, salts and surfactants.

### Claim 2 (depends on 1)

The method of claim 1, wherein the concentration of said target biomarker in said final solution is at least 50-fold higher than the concentration of the target biomarker in said sample solution.

### Claim 3 (depends on 1)

The method of claim 1, wherein the porous material is selected from the group consisting of fiber-glass paper, cotton-based paper, single-layer matrix paper and polyolefin foam pad.

### Claim 4 (depends on 1)

The method of claim 1, wherein said polymers are selected from the group consisting of polyalkylene glycols, poly(oxyalkylene)polymers, poly(oxyalkylene)copolymers, polyvinyl pyrrolidone, polyvinyl alcohol, polyvinyl caprolactam, polyvinyl methylether, alkoxylated surfactants, alkoxylated starches, alkoxylated cellulose, alkyl hydroxyalkyl cellulose, silicone-modified polyethers, poly N-isopropylacrylamide, polyethylene glycol, polypropylene glycol and dextran.

### Claim 5 (depends on 1)

The method of claim 1, wherein said salts are selected from the group consisting of kosmotropic salts, chaotropic salts, inorganic salts having a cation of trimethyl ammonium, triethyl ammonium, tripropyl ammonium, tributyl ammonium, tetramethyl ammonium, tetraethyl ammonium, tetrapropyl ammonium or tetrabutyl ammonium, and an anion of phosphate, sulphate, nitrate, chloride or hydrogen carbonate, NaCl, Na3PO4, K3PO4, Na2SO4, potassium citrate, (NH4)2SO4, sodium citrate, sodium acetate, ammonium acetate, and any combinations thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein said surfactants are selected from the group consisting of nonionic surfactants, detergents, Triton-X, Igepal CA-630 and Nonidet P-40.

### Claim 7 (depends on 1)

The method of claim 1, wherein the sample solution comprises one or more of blood, plasma, serum, urine, saliva, fecal matters and bodily discharges.

### Claim 8 (depends on 1)

The method of claim 1, wherein the target biomarker is concentrated by up to 100-fold.

### Claim 9 (depends on 1)

The method of claim 1, wherein the disease is cancer.

### Claim 10 (depends on 1)

The method of claim 1, wherein the diagnostic assay is selected form the group consisting of Enzyme-Linked Immune Sorbent Assay (ELISA), Polymerase Chain Reaction (PCR), Radioimmunoassay (RIA), proteomic-based approach, blotting procedure, immunoassay, enzymatic assay and GC/MS.

### Claim 11 (depends on 1)

The method of claim 1, wherein said ATPS components comprise polyethylene glycol, SDS, Triton-X114 and Na2SO4.

### Claim 12 (depends on 11)

The method of claim 11, wherein said polyethylene glycol is PEG4600.

### Claim 13 (depends on 1)

The method of claim 1, wherein said ATPS components comprise 20% (w/w) PEG4600, 2% (w/w) SDS, 16% (w/w) Triton-X114 and 18.5% (w/w) Na2SO4.
